How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/e-coli-pelvic-inflammatory-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

E. Coli Pelvic Inflammatory Disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

E. Coli Pelvic Inflammatory Disease (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating E. Coli Pelvic Inflammatory Disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zosyn	TAZOBACTAM	Merck Sharp & Dohme B.V.	beta Lactamase Inhibitor		1993-01-01
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in E. Coli Pelvic Inflammatory Disease
Pai Holdings Pharm · 2 drugs in E. Coli Pelvic Inflammatory Disease
Bristol-Myers Squibb · 1 drug in E. Coli Pelvic Inflammatory Disease
Merck Sharp & Dohme B.V. · 1 drug in E. Coli Pelvic Inflammatory Disease
Sterimax · 1 drug in E. Coli Pelvic Inflammatory Disease
Tel-Aviv Sourasky Medical Center · 1 drug in E. Coli Pelvic Inflammatory Disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in E. Coli Pelvic Inflammatory Disease:

Cite this brief

Drug Landscape (2026). E. Coli Pelvic Inflammatory Disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/e-coli-pelvic-inflammatory-disease. Accessed 2026-06-10.

E. Coli Pelvic Inflammatory Disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing